Seoul Pharma Co., Ltd (KOSDAQ: 018680)
South Korea
· Delayed Price · Currency is KRW 3,420.00
+25.00 (0.74%)
Nov 15, 2024, 9:00 AM KST
Seoul Pharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 | 2006 - 2005 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '12 Sep 30, 2012 | Dec '11 Dec 31, 2011 | Dec '10 Dec 31, 2010 | Dec '09 Dec 31, 2009 | Dec '08 Dec 31, 2008 | Dec '07 Dec 31, 2007 | 2006 - 2005 |
| Revenue | 42,277 | 43,821 | 40,419 | 31,814 | 24,751 | 16,727 | Upgrade
|
| Revenue Growth (YoY) | -4.77% | 8.42% | 27.05% | 28.54% | 47.97% | -10.61% | Upgrade
|
| Cost of Revenue | 20,576 | 19,016 | 16,061 | 11,269 | 9,115 | 6,465 | Upgrade
|
| Gross Profit | 21,701 | 24,804 | 24,358 | 20,545 | 15,635 | 10,262 | Upgrade
|
| Selling, General & Admin | 20,304 | 23,026 | 21,911 | 17,731 | 13,968 | 11,949 | Upgrade
|
| Research & Development | - | - | - | 754.67 | 803.42 | 857.46 | Upgrade
|
| Other Operating Expenses | -187.08 | -107.42 | -89.91 | 68.14 | 42.37 | 35.84 | Upgrade
|
| Operating Expenses | 20,117 | 22,918 | 21,821 | 19,306 | 15,329 | 13,149 | Upgrade
|
| Operating Income | 1,584 | 1,886 | 2,537 | 1,239 | 306.38 | -2,887 | Upgrade
|
| Interest Expense | -856.11 | -691.29 | -505.65 | -279.63 | -157.04 | -45.16 | Upgrade
|
| Interest & Investment Income | 103.91 | 31.75 | 12.02 | 22.94 | 60.36 | 74.92 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | 20.76 | -10.32 | -1.03 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | -4.74 | 142.29 | 46.44 | Upgrade
|
| EBT Excluding Unusual Items | 831.57 | 1,227 | 2,043 | 998.14 | 341.67 | -2,812 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 11.75 | 67.6 | 8.53 | Upgrade
|
| Pretax Income | 831.57 | 1,227 | 2,043 | 1,010 | 409.27 | -2,804 | Upgrade
|
| Income Tax Expense | -221.67 | -106.74 | 629.83 | -171.02 | -132.77 | -293.96 | Upgrade
|
| Net Income | 1,053 | 1,333 | 1,413 | 1,181 | 542.04 | -2,510 | Upgrade
|
| Net Income to Common | 1,053 | 1,333 | 1,413 | 1,181 | 542.04 | -2,510 | Upgrade
|
| Net Income Growth | -16.14% | -5.66% | 19.69% | 117.86% | - | - | Upgrade
|
| Shares Outstanding (Basic) | - | - | - | 6 | 6 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | - | - | - | 6 | 6 | 6 | Upgrade
|
| EPS (Basic) | - | - | - | 188.94 | 86.73 | -401.53 | Upgrade
|
| EPS (Diluted) | - | - | - | 188.94 | 86.73 | -401.53 | Upgrade
|
| EPS Growth | - | - | - | 117.86% | - | - | Upgrade
|
| Free Cash Flow | -10,551 | -574.48 | 829.86 | -4,875 | -3,081 | -2,895 | Upgrade
|
| Free Cash Flow Per Share | - | - | - | -779.93 | -493.02 | -463.15 | Upgrade
|
| Dividend Per Share | - | - | - | 40.000 | - | - | Upgrade
|
| Gross Margin | 51.33% | 56.60% | 60.26% | 64.58% | 63.17% | 61.35% | Upgrade
|
| Operating Margin | 3.75% | 4.30% | 6.28% | 3.89% | 1.24% | -17.26% | Upgrade
|
| Profit Margin | 2.49% | 3.04% | 3.50% | 3.71% | 2.19% | -15.00% | Upgrade
|
| Free Cash Flow Margin | -24.96% | -1.31% | 2.05% | -15.32% | -12.45% | -17.31% | Upgrade
|
| EBITDA | - | - | 3,458 | 2,304 | 1,327 | -1,962 | Upgrade
|
| EBITDA Margin | - | - | 8.56% | 7.24% | 5.36% | -11.73% | Upgrade
|
| D&A For EBITDA | - | - | 921.42 | 1,065 | 1,021 | 925.08 | Upgrade
|
| EBIT | 1,584 | 1,886 | 2,537 | 1,239 | 306.38 | -2,887 | Upgrade
|
| EBIT Margin | 3.75% | 4.30% | 6.28% | 3.89% | 1.24% | -17.26% | Upgrade
|
| Effective Tax Rate | - | - | 30.82% | - | - | - | Upgrade
|
| Revenue as Reported | - | - | - | 31,814 | 24,751 | 16,727 | Upgrade
|
| Advertising Expenses | - | - | - | 2,289 | 3,500 | 2,478 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.